Teva Pharmaceutical Industries Ltd. — Director's Dealing 2025

Feb 19, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2025-02-15

Reporting Person: Francis Richard D (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-15	Ordinary Shares	M	161655	—	Acquired	284950	Direct
2025-02-18	Ordinary Shares	S	75506	$16.9478	Disposed	209444	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-15	Restricted Share Units	$	M	161655	Disposed		Ordinary Shares (161655)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.885 to $17.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: Restricted share units were granted on February 15, 2023 with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.